PROJECT 12. Protocal Review

$120,631P30FY2016CANIH

University Of Kentucky, Lexington KY

Investigators

Linked publications & trials

Paper 39724002 Paper 39653069 Paper 39582356 Paper 39388079 Paper 39369769 Paper 39323971 Paper 39281865 Paper 39259913 Paper 39243301 Paper 39243032 Paper 39235683 Paper 39200173 Paper 39161271 Paper 39079076 Paper 39068202 Paper 39057706 Paper 39054557 Paper 39015956 Paper 38979225 Paper 38968071 Paper 38900572 Paper 38893116 Paper 38885192 Paper 38877143 Paper 38809305 Paper 38801884 Paper 38794641 Paper 38771046 Paper 38754493 Paper 38703412 Paper 38610999 Paper 38609261 Paper 38591114 Paper 38555305 Paper 38502173 Paper 38452212 Paper 38446540 Paper 38423808 Paper 38386344 Paper 38370737 Paper 38342820 Paper 38322427 Paper 38315842 Paper 38295319 Paper 38282364 Paper 38274288 Paper 38265267 Paper 38247803 Paper 38233562 Paper 38228141 Paper 38219963 Paper 38212533 Paper 38200423 Paper 38194612 Paper 38128183 Paper 38113411 Paper 38104416 Paper 38104159 Paper 38101690 Paper 38101582 Paper 38069382 Paper 38056245 Paper 38052269 Paper 38006531 Paper 38001642 Paper 37992808 Paper 37988371 Paper 37982534 Paper 37967292 Paper 37904519 Paper 37887269 Paper 37869728 Paper 37866630 Paper 37847682 Paper 37846852 Paper 37816729 Paper 37762518 Paper 37732829 Paper 37673172 Paper 37664066 Paper 37626877 Paper 37609352 Paper 37594272 Paper 37550596 Paper 37548565 Paper 37540490 Paper 37512481 Paper 37510595 Paper 37502903 Paper 37475584 Paper 37405918 Paper 37373873 Paper 37370804 Paper 37369852 Paper 37345464 Paper 37333199 Paper 37315874 Paper 37279147 Paper 37222667 Paper 37220097

Abstract

The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator-initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.

View original record on NIH RePORTER →